Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Invitae Acquires Jungla, Scripps Research-Led Group Gets $129 Million Grant for HIV Vaccine, Charles River Plots 2020 Opening of South San Francisco Lab

  • 2019-07-11T22:15:00.000+0000
  • California
  • Author: Lauren Panetta

7/11/19 – FierceBiotech
GSK Hires Branson from Genentech to Boost AI Team

7/11/19 – GenomeWeb
Invitae Acquiring Jungla for up to $65M to Enhance Variant Interpretation

7/10/19 – San Francisco Business Times
Biotech Rockstars Snag Top Posts at Fast-Growing Peninsula Company, BridgeBio

7/10/19 – FierceBiotech
FDA Accepts BLA Filing for Sanofi's Rival to J&J's Darzalex

7/10/19 – San Diego Union-Tribune
Scripps Research-Led Group Gets $129 Million Grant for HIV Vaccine

7/10/19 – FierceBiotech
Charles River Plots 2020 Opening of South San Francisco Lab

7/9/19 – GenomeWeb
FBI Approves Thermo Fisher NGS Forensic Profiling Solution

7/7/19 – San Diego Union-Tribune
UCSD to Send ‘Mini-Brains’ to International Space Station for Neural Disease Research

7/1/19 – MedCityNews
Biogen Spinal Muscular Atrophy Drug Shows Strong Data in Long-Term Follow-up

7/1/19 – Boehringer Ingelheim
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation

7/1/19 – FierceBiotech
In conversation with Raj Krishnan, CEO of Biological Dynamics
6/28/19 – Pfizer
Pfizer Presents Initital Clinical Data on Phase 1B Gene Therapy Study for Duchenne Muscular Dystrophy (DMD)

6/28/19 – FierceBiotech
Sierra Doubles Down on Ex-Gilead Drug

6/27/19 – BillionToOne
BillionToOne launches UNITY™ prenatal screen

6/27/19 – OncoSec Medical Incorporated
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers

6/26/19 – MedCityNews
Frontier Medicines Launches with $67M Series A, Hopes to Go After ‘Undruggable’ Targets

6/25/19 – MedCityNews
AbbVie to Buy Botox Maker Allergan for $63B

6/22/19 – MEI Pharma
MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

6/20/19 – Turning Point Therapeutics
Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study